SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals

International Journal of Molecular Sciences
Yalena PradoLuis A Salazar

Abstract

The use of statins as the preferred lipid-lowering therapy has clearly demonstrated its efficacy in the treatment of hypercholesterolemia, reducing also the risk of coronary events and cardiovascular disease mortality. In this study, we assessed single nucleotide polymorphisms (SNPs) in the SLCO1B1 gene and their effect on atorvastatin response. We included 129 Chilean hypercholesterolemic patients undergoing 10 mg/day of atorvastatin therapy during 4 weeks. Lipid profile was determined before and after drug administration. Genotyping of SLCO1B1 rs4149056 (c.521T>C) SNP was performed with allele-specific polymerase chain reaction, whilst polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used for genotyping the SLCO1B1 rs2306283 (c.388A>G) variant. After statin therapy, concentrations of TC, LDL-C and TG had a decrease from baseline (p < 0.05). Also, HDL-C levels increased (p < 0.05). Minor allele frequencies for the rs2306283 and rs4149056 variants were 0.547 and 0.136, respectively. LDL-C response to atorvastatin was not associated with the SLCO1B1 rs4149056 nor the rs2306283 polymorphisms (p > 0.05). However, the latter SNP was associated with HDL-C variability after atorvastatin medication (p ...Continue Reading

References

Jan 15, 2000·Journal of the American College of Cardiology·C J VaughanC T Basson
Jun 14, 2003·Pharmacology & Therapeutics·Anthony S WierzbickiAlbert Ferro
Jun 18, 2003·Clinical Pharmacology and Therapeutics·Yohei NishizatoYuichi Sugiyama
Apr 30, 2004·Clinical Pharmacology and Therapeutics·Jessica MwinyiThomas Gerloff
Apr 18, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Priscilla C JaramilloLuis A Salazar
Nov 17, 2006·Pharmacogenetics and Genomics·Marja K PasanenMikko Niemi
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Inder M SinghBenjamin J Ansell
Jul 25, 2008·The New England Journal of Medicine·UNKNOWN SEARCH Collaborative GroupR Collins
Nov 4, 2009·The Pharmacogenomics Journal·S P R RomaineA J Balmforth
Apr 8, 2010·Journal of Lipid Research·Menno VergeerJan Albert Kuivenhoven
Apr 22, 2010·Basic & Clinical Pharmacology & Toxicology·Annikka KalliokoskiMikko Niemi
Oct 22, 2011·International Journal of Molecular Sciences·Alice C RodriguesRosario D C Hirata
Nov 29, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Alexy RosalesLuis A Salazar
Apr 17, 2012·Clinical Chemistry and Laboratory Medicine : CCLM·Vinicius A SorticaMara H Hutz
Jan 25, 2014·PLoS Currents·Alison Stewart

❮ Previous
Next ❯

Citations

Jun 21, 2016·Advanced Drug Delivery Reviews·Fanfan ZhouMichael Murray
Oct 20, 2018·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Xiangyu WuXiping Xu
Aug 10, 2017·Expert Opinion on Drug Metabolism & Toxicology·Elliot Berinstein, Andrew Levy
Aug 24, 2017·Journal of Clinical Pharmacy and Therapeutics·Y PradoL A Salazar

❮ Previous
Next ❯

Methods Mentioned

BETA
Genotyping
Assay
PCR
electrophoresis

Software Mentioned

GraphPad Prism
GraphPad
StepOne

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.